Comparison · NCT02486211-427c76cf
Amantadine vs Placebo: Rate of Awakening (Number of Patients Who Are Able to Follow Commands)
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
2 sourcestrial-comparisons-2026-03-23-0.1.0
Cite this record
ConductScience Library. Amantadine vs Placebo: Rate of Awakening (Number of Patients Who Are Able to Follow Commands). Trial comparisons, record NCT02486211-427c76cf. Release trial-comparisons-2026-03-23-0.1.0, 23 Mar 2026. https://conductscience.org/library/comparisons/NCT02486211-427c76cf
On this page
Measures6
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
| Measure | Value | 95% interval, lower | 95% interval, upper | Method | Note |
|---|---|---|---|---|---|
| Risk in group 1 | 0.286 | 0.0822 | 0.641 | wilson | |
| Risk in group 2 | 0.286 | 0.0822 | 0.641 | wilson | |
| Risk difference, group 1 minus group 2 | 0 | -0.409 | 0.409 | newcombe hybrid score | |
| Risk ratio, group 1 over group 2 | 1 | 0.191 | 5.24 | log | |
| Odds ratio, group 1 over group 2 | 1 | 0.0984 | 10.2 | log | |
| Number needed to treat | from the risk difference interval | the two groups' risks are equal |
Source ClinicalTrials.gov
Groups2
Group 2 names the comparator: placebo.
| Group | Title | Description | With the outcome | Analysed | ClinicalTrials.gov code |
|---|---|---|---|---|---|
| Group 1 | Amantadine | 100mg Amantadine administered at 0600 and 1200 via mouth, gastric tube or duo-tube.~Amantadine: 100mg twice per day for 7 days at 0600 and 1200 | 2 | 7 | OG000 |
| Group 2 | Placebo | Placebo medication administered at 0600 and 1200 via mouth, gastric tube or duo-tube.~Placebo: Placebo comparator | 2 | 7 | OG001 |
Source ClinicalTrials.gov
Outcome
- Type
- PRIMARY
- Title
- Rate of Awakening (Number of Patients Who Are Able to Follow Commands)
- Description
Defined as the ability to follow commands (i.e. wiggle your toes open your eyes squeeze my fingers. This corresponds to a Full Outline of Unresponsiveness motor score of 4. FOUR (full outline of unresponsiveness) measures the following: Eye Response, Motor Response, Brainstem Reflexes, and Respirations.
- Time frame
- up to 28 days
- Population
Source ClinicalTrials.gov
Trial
- Title
- Amantadine to Speed Awakening After Cardiac Arrest
- NCT number
- NCT02486211
- Phases
- PHASE2
- Conditions
- Coma, Heart Arrest, Anoxia
- Interventions
- Amantadine, Placebo
- Lead sponsor
- Jon Rittenberger, MD
- Results first posted
- 2019-12-04
- Results on ClinicalTrials.gov
- https://clinicaltrials.gov/study/NCT02486211?tab=results
Source ClinicalTrials.gov
Source
- Release
- trial-comparisons-2026-03-23-0.1.0
- Release manifest SHA-256
- f66225897fbf258b57ea10bdacfd0347d3cdfda93f7f5685234b7e06ea36fa57
- AACT copy
- 2026-03-23
- Tables read
- outcome_counts.parquet, outcome_measurements.parquet, outcomes.parquet, reported_event_totals.parquet, reported_events.parquet, result_groups.parquet, studies.parquet, ctgov_trial.parquet
Source ClinicalTrials.gov
Sources 2
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.
For software
Read this comparison from software.
The record is JSON. No key.
GET https://conductscience.org/api/comparisons/v1/NCT02486211-427c76cf